1. Home
  2. MRUS vs PRVA Comparison

MRUS vs PRVA Comparison

Compare MRUS & PRVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MRUS
  • PRVA
  • Stock Information
  • Founded
  • MRUS 2003
  • PRVA 2007
  • Country
  • MRUS Netherlands
  • PRVA United States
  • Employees
  • MRUS N/A
  • PRVA N/A
  • Industry
  • MRUS Biotechnology: Pharmaceutical Preparations
  • PRVA Retail: Computer Software & Peripheral Equipment
  • Sector
  • MRUS Health Care
  • PRVA Technology
  • Exchange
  • MRUS Nasdaq
  • PRVA Nasdaq
  • Market Cap
  • MRUS 2.7B
  • PRVA 2.8B
  • IPO Year
  • MRUS 2016
  • PRVA 2021
  • Fundamental
  • Price
  • MRUS $42.77
  • PRVA $25.07
  • Analyst Decision
  • MRUS Strong Buy
  • PRVA Strong Buy
  • Analyst Count
  • MRUS 14
  • PRVA 14
  • Target Price
  • MRUS $87.00
  • PRVA $27.57
  • AVG Volume (30 Days)
  • MRUS 786.0K
  • PRVA 620.7K
  • Earning Date
  • MRUS 05-07-2025
  • PRVA 05-08-2025
  • Dividend Yield
  • MRUS N/A
  • PRVA N/A
  • EPS Growth
  • MRUS N/A
  • PRVA N/A
  • EPS
  • MRUS N/A
  • PRVA 0.12
  • Revenue
  • MRUS $54,732,000.00
  • PRVA $1,801,244,000.00
  • Revenue This Year
  • MRUS $26.81
  • PRVA $88.96
  • Revenue Next Year
  • MRUS $23.85
  • PRVA $10.70
  • P/E Ratio
  • MRUS N/A
  • PRVA $212.33
  • Revenue Growth
  • MRUS N/A
  • PRVA 6.79
  • 52 Week Low
  • MRUS $33.19
  • PRVA $15.92
  • 52 Week High
  • MRUS $61.61
  • PRVA $26.04
  • Technical
  • Relative Strength Index (RSI)
  • MRUS 49.60
  • PRVA 64.45
  • Support Level
  • MRUS $37.92
  • PRVA $22.51
  • Resistance Level
  • MRUS $46.36
  • PRVA $23.78
  • Average True Range (ATR)
  • MRUS 2.56
  • PRVA 0.75
  • MACD
  • MRUS -0.22
  • PRVA 0.11
  • Stochastic Oscillator
  • MRUS 57.46
  • PRVA 71.51

About MRUS Merus N.V.

Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.

About PRVA Privia Health Group Inc.

Privia Health Group Inc is a technology-driven, national physician-enablement company. It collaborates with medical groups, health plans, and health systems to optimize physician practices, improve patient experiences, and reward doctors for delivering high-value care in both in-person and virtual care settings.

Share on Social Networks: